Company / Total Assets
Ultragenyx Pharmaceutical Inc. Total Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$1.5B
FY2025
5-year range
$1.5B / $1.5B
FY2021-FY2025
Trend
+1.9%
vs FY2024
Sector context
#52 of 214
Health Care
What the data says
Ultragenyx Pharmaceutical Inc.'s total assets of $1.5B is higher than 76% of companies in the Health Care sector (FY2025). Total Assets has fluctuated over the past 10 years, ranging from $491M in FY2017 to $1.8B in FY2020.
Based on SEC 10-K filings.
$1.5B in FY2025 with a 5-year CAGR of -2.7%. Top quartile in the Health Care sector.
Improved from $1.5B to $1.5B over the past 2 years.
Health Care sector context is included.
Total Assets over time
Growth rates
- 3-Year CAGR
- -0.3%
- 5-Year CAGR
- -2.7%
- 10-Year CAGR
- -
Sector benchmark
Top 24% in Health CareTop 24% of 214This company $1.5B Sector average $7.5B
▼
-79.5% below sector average
Key checks
Key Insights
- 5-year CAGR of -2.7%, indicating a declining trend.
- In FY2025, total assets increased 1.9% year-over-year.
- Ranks #52 out of 214 companies in the Health Care sector.
- Peak total assets was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score -2.91 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.5B | +1.9% |
| FY2024 | $1.5B | +0.8% |
| FY2023 | $1.5B | -3.5% |
| FY2022 | $1.5B | +1.5% |
| FY2021 | $1.5B | -13.5% |
| FY2020 | $1.8B | +55.0% |
| FY2019 | $1.1B | +57.8% |
| FY2018 | $719.6M | +46.6% |
| FY2017 | $490.8M | -9.2% |
| FY2016 | $540.6M | -3.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026